How to use price erosion curves, Paragraph IV filings, Orange Book patent analysis, and biosimilar IP valuation to build a […]
Generic Entry Pricing: The Complete Drug Price Data Playbook for Portfolio Managers Read Post »
Generic drugs account for nearly 90% of all prescriptions dispensed in the United States yet represent only about 20% of
DrugPatentWatch, a provider of global biopharmaceutical business intelligence, has entered into a partnership with Adis. The partner will enhance Adis’
DrugPatentWatch Partners with Adis: Helping Drug Companies Make Better Decisions Read Post »
Branded generics are generic drugs that have been given proprietary brand names. They have a small, but profitable place in the U.S. pharmaceutical market.
Branded Generics and Why They’re Profitable Read Post »
Pre-ANDA Litigation Strategy: The Complete Playbook for Building Unbreakable Drug Patent Portfolios For IP counsel, portfolio managers, R&D leads, and
Pharmaceutical life cycle management begins earlier and ends later to maximize stakeholder value in all phases of drug development.
For readers following the the Biologic Patent Transparency Act, DrugPatentWatch has recently been cited in an article describing the act as
DrugPatentWatch in the news: The Biologic Patent Transparency Act. Read Post »
1. What This Article Covers and Why It Matters Now The baseline 20-year patent term for a small molecule drug
Healthcare systems including hospitals are taking care-related and business-related steps to cope with rapidly increasing drug prices.
Sign in or create a free account to read this DrugPatentWatch article
